Our Products

We have selected 25 out of over 100 products available as biosimilar candidates for the US and global markets; the following products are currently available for licensing; several more cytokines and TNF blocker antibodies are coming in 2019.

insulinglargine.png

Insulin glargine markets are rising sharply

Insulin glargine is expected to exceed Humira sales by 2020; KBL can file it under 505(b)(2) before March 2020.

kbl-124 (insulin glargine)

Clinical. FDA advises we are ready to file IND, protocols, timelines and cost finalized. Ready for sponsoring partner. URGENT to meet 3/2020 deadline to quaify for 505 (b)(2) filing. Click here to see the status of insulin glargine biosimilars.


bevacizumab.png

Bevacizumab, the first anticancer antibody approved by FDA

KBL-125 (bevacizumab)

Clinical. FDA meetings held, FDA states product in advanced stage for Type 2; protocols, time and cost finalized. Ready for sponsoring partner. Click here to see the status of bevacizumab biosimilars.

KBL-126 (Filgrastim)[

Future product. Click here to see the status of filgrastim biosimilars.

KBL-127 (Pegfilgrastim)

Future product. Click here to see the status of pegfilgrastim biosimilars.


Screenshot 2017-12-14 10.40.15.png

Adalimumab, the largest, the most sought-after product

Subject to non-compete. Licensing available not before 31 December, 2018


Screenshot 2017-12-14 10.44.53.png

Liraglutide completes the insulin group

KBL-129 (Insulin aspart)

Process development. FDA meeting 2018. Click here to see the status of insulin aspart biosimilars.

KBL-130 (Liraglutide)

Process development. FDA meeting 2018. Click here to see the status of liraglutide biosimilars.


trastuzumab.png

Trastuzumab is the second largest antibody for cancer treatment

 

KBL-131 (Trastuzumab)

Pre-clinical. FDA meeting 2018. Click here to see the status of trastuzumab biosimilars.


Screenshot 2017-12-14 11.21.25.png

Epoetin and darbepoietin are the most established biosimilars

 

KBL-132 (Erythropoietin alfa)

Process development. FDA meeting 2019. Click here to see the status of erythropoietin biosimilars.

KBL-133 (darbepoietin alfa)

Process development. FDA Meeting 2018. Click here to see the status of darbepoietin biosimilars.